Ongeno advances MS therapy, securing PLN 15M to finalize groundbreaking stem cell treatment by 2025.
Milestone Achieved: Positive Validation of Stem Cell Therapy
Ongeno, a portfolio company of JRH ASI, has successfully completed the validation phase of its groundbreaking stem cell therapy for multiple sclerosis (MS). This achievement paves the way for the final stage of the medical experiment, which is set to conclude by the end of 2025.
Significant Funding and Promising Results
The company raised PLN 15M through the issuance of new shares, valuing Ongeno at PLN 300M. Developed by Dr. Wojciech Orłowski, the therapy involves harvesting bone marrow, isolating stem cells, and transplanting them intravenously into patients. Initial results have shown significant and long-lasting improvements, with some patients achieving near-complete remission and resuming normal activities.
Future Outlook: Towards Commercialization
The final phase will treat 6-10 patients, with the first outcomes expected within three months. Ongeno aims to commercialize the therapy by 2025, planning to scale up to 200 procedures annually.